scholarly journals P367 Weight patterns in biologicals treated Inflammatory bowel disease cohort

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S385-S386
Author(s):  
P Kaazan ◽  
Z Tan ◽  
P Maiyani ◽  
M Mickenbecker ◽  
S Edwards ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Weight Gain ◽  
Treatment Group ◽  
Latent Class Analysis ◽  
Bowel Disease ◽  
Latent Class ◽  
Large Weight ◽  
Baseline Weight ◽  
Inflammatory Bowel ◽  
Over Time

Abstract Background Biologic therapies are effective at inducing and maintaining remission in patients with inflammatory bowel disease (IBD). Previous studies have associated TNF-a inhibitors with weight gain, however it is unclear if this is a class-related effect or a manifestation of clinical remission. We performed this retrospective study to compare weight changes from baseline across different biological classes, examine weight patterns over time and assess characteristics and associations within each (sub)groups. Methods Adult patients with IBD who received any biological therapy for at least 12 months, between 2008 and 2020, were identified from prospectively maintained records at two IBD units in Australia. Data collected included demographics; weight and BMI at baseline, 6, 12, 24 and 48 months; IBD type and phenotype; baseline endoscopy, baseline haemoglobin, C-reactive protein (CRP) and albumin; combination or monotherapy; initial steroid therapy and frequency of biologic infusion. Patients with missing data were excluded. A linear mixed-effects model was performed for the outcome of weight change from baseline, including the interaction of treatment group and time period. A latent class analysis was then performed, assigning patients to weight trajectory groups, and univariate ordinal logistic regressions were used to explore possible associations between membership of each group (the outcome) against various predictive factors. Results Of 294 patients (156 females), 165 received Infliximab (IFX), 68 Adalimumab (ADA), 36 Vedolizumab (VDZ) and 25 Ustekinumab (UST). There was a statistically significant interaction between time and treatment group with a significant weight gain over time in both the IFX and VDZ groups. After adjusting for baseline weight and inflammatory markers, significant weight gain was found for IFX vs ADA and VDZ vs ADA at most time points (Fig.1). Significantly less weight gain was seen in those with a higher initiation weight. Each 10kg increase in baseline weight resulted in 0.5kg less weight gain. This effect also held true for BMI. Latent class analysis identified three weight trajectories: 57.4% of patients had small weight loss (-2.3kg), 37.8% small weight gain (6.6 kg) and 4.8% large weight gain (24.3 kg). Baseline BMI inversely influenced weight gain; with every 1 unit increase in BMI, reducing the odds of large weight gain by 8%. Being female, having an initiation CRP£5 or albumin>35 also reduced the odds of large weight gain. Conclusion Weight gain in biological-treated IBD patients appears to be associated with male gender, active baseline inflammation and the type of drug used.

scholarly journals Trajectories of Fatigue in Inflammatory Bowel Disease

2021 ◽  
Author(s):  
Birte Klusmann ◽  
Joke Fleer ◽  
K Annika Tovote ◽  
Rinse K Weersma ◽  
Hendrik M van Dullemen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Latent Class ◽  
Medical Center ◽  
Well Being ◽  
Fatigue Severity ◽  
Inflammatory Bowel ◽  
The University ◽  
Over Time

Abstract Background Fatigue is one of the most frequently reported symptoms by patients with inflammatory bowel disease (IBD), both during active disease phases as well as during clinical remission. This study addressed whether different trajectories of fatigue over time can be identified among patients with IBD. Subsequently, we compared the demographic and clinical characteristics between trajectories. Methods The current study included 849 patients with IBD diagnosed with either Crohn disease (CD; n = 511) or ulcerative colitis (UC; n = 338) who visited the University Medical Center in Groningen (the Netherlands) at least 3 times during a 9-year follow-up. We conducted latent class growth analyses to identify distinct trajectories. Results In all patients with IBD (and in the subgroup with CD), we found 5 trajectories for fatigue. In the UC subgroup, we found 4 fatigue trajectories. One trajectory present in both patients with CD (11.45%) and patients with UC (4.75%) was characterized by chronic elevated levels of fatigue across time. Women and parents were more prevalent in trajectories with higher fatigue severity. We also found significant associations among the fatigue trajectories with disease activity and psychological well-being. Conclusions The results clearly showed the existence of distinct fatigue paths over time in patients with IBD. Those reporting more chronic elevated levels of fatigue also reported greater disease activity and reduced well-being. Therefore, reducing disease activity may be important for the treatment of fatigue. In addition, given the significant association with well-being, it is possible that reducing fatigue may improve self-reported well-being.

T1257 Characterization of Changes of Serum Anti-Glycan Antibodies in Individual Patients Over Time in Inflammatory Bowel Disease (IBD)

2010 ◽  
Vol 138 (5) ◽  
pp. S-522
Author(s):  
Florian Rieder ◽  
Stephan Schleder ◽  
Alexandra Wolf ◽  
Anja Schirbel ◽  
Andre Franke ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Over Time

Leukemia in hospitalized patients with inflammatory bowel disease: An analysis of the National Inpatient Sample (NIS) database.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10576-10576
Author(s):  
Colin Wikholm ◽  
Shiva Shankar Vangimalla ◽  
Ehab Abaza ◽  
Akram Ahmad ◽  
Ioannis Pothoulakis ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Age Groups ◽  
Black Patients ◽  
Increased Risk ◽  
Leukemia Diagnosis ◽  
Inflammatory Bowel ◽  
Over Time ◽  
White Patients

10576 Background: Inflammatory bowel disease (IBD) and use of immunosuppressive therapy in IBD is linked with increased risk of leukemia. We studied the NIS database from 2003-2017 to analyze trends in any type of leukemia in IBD hospitalizations over time and examined the role of age, sex, and race. Methods: We analyzed NIS data of all adult hospitalizations for ulcerative colitis (UC) or Crohn’s disease (CD) with any type of leukemia as a primary or secondary diagnosis using validated ICD 9/10 codes. Age, sex, and racial demographics were collected. Trend analysis of leukemia was performed with Cochran-Armitage and Jonckheere-Terpstra tests. Results: Overall Trends: From 2003-2017, a total of 11,385 of 2,235,413 (0.51%) CD hospitalizations and 8,105 of 1,324,746 (0.61%) UC hospitalizations contained diagnosis of leukemia. An increase in leukemia was seen in both CD and UC group from 0.24% to 0.79% (pTrend < 0.0001) and 0.28% to 0.81% (pTrend < 0.0001) respectively. Sex: In both UC and CD patients, leukemia diagnoses were predominantly male in 2003 but approximated a near 1:1 ratio by 2017 (Table). In CD, the proportion of female (FEM) leukemia diagnoses grew from 31.33% to 45.05% from 2003 to 2017 (pTrend = 0.1898). In UC, the proportion of female leukemia diagnoses grew from 27.49% to 45.79% from 2003 to 2017 (pTrend = 0.0030). Age: Leukemia was more common with increasing age, with no significant changes in proportion of cases between age groups over time (pTrend >.05). Ethnicity: White patients composed 87.80% and 84.24% of leukemia diagnoses in CD and UC, respectively. In CD, an increasing proportion of leukemia diagnoses occurred in black (BK) patients, and a decreasing proportion occurred in white patients (pTrends <.0001; Table 1) during the study time. No trends in race were observed in the UC group (pTrend = 0.4229). Conclusions: Our study showed an increased prevalence of leukemia in CD and UC hospitalizations from 2003-2017 which may be related to increasing use of immunosuppressants such as anti-TNF medications. In both CD and UC, leukemia was male-predominant, but increasingly female by 2017. Rate of leukemia diagnosis increased with age. In the CD group but not the UC group, leukemia was increasingly prevalent in black patients.[Table: see text]

scholarly journals Preferences of Adult Patients With Inflammatory Bowel Disease for Attributes of Clinical Trials: Evidence From a Choice-Based Conjoint Analysis

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Dallas Wood ◽  
Katherine Kosa ◽  
Derek Brown ◽  
Orna G Ehrlich ◽  
Peter D R Higgins ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Inflammatory Bowel Disease ◽  
Clinical Trials ◽  
Bowel Disease ◽  
Latent Class ◽  
Open Label ◽  
Monetary Compensation ◽  
Open Label Extension ◽  
Inflammatory Bowel ◽  
New Treatments

Abstract Background Clinical trial recruitment is the rate-limiting step in developing new treatments. To understand inflammatory bowel disease (IBD) patient recruitment, we investigated two questions: Do changes in clinical trial attributes, like monetary compensation, influence recruitment rates, and does this influence differ across subgroups? Methods We answered these questions through a conjoint survey of 949 adult IBD patients. Results Recruitment rates are influenced by trial attributes: small but significant increases are predicted with lower placebo rates, reduced number of endoscopies, less time commitment, open label extension, and increased involvement of participant’s primary GI physician. A much stronger effect was found with increased monetary compensation. Latent class analysis indicated three patient subgroups: some patients quite willing to participate in IBD trials, some quite reluctant, and others who can be persuaded. The persuadable group is quite sensitive to monetary compensation, and payments up to US$2,000 for a 1-year study could significantly increase recruitment rates for IBD clinical trials. Conclusions This innovative study provides researchers with a framework for predicting recruitment rates for different IBD clinical trials.

Understanding the Cause of Weight Gain in Patients With IBD on Anti-TNF Medications

2019 ◽  
Vol 26 (1) ◽  
pp. 132-133
Author(s):  
Rachel W Winter ◽  
Sonia Friedman
Keyword(s):  
Inflammatory Bowel Disease ◽  
Weight Gain ◽  
Tumor Necrosis Factor ◽  
Disease Activity ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Inflammatory Bowel ◽  
Necrosis Factor

This article investigates the factors that are associated with weight gain in patients on anti–tumor necrosis factor (anti-TNF) medications. What remains unanswered is whether remission of disease activity, the anti-TNF medications themselves, or both are responsible for abnormal weight gain in patients with inflammatory bowel disease.

Tu1113 Fecal Microbial Composition of Inflammatory Bowel Disease (IBD) Patients With Changing Disease Activity Over Time

2013 ◽  
Vol 144 (5) ◽  
pp. S-765-S-766
Author(s):  
Edgar Wills ◽  
Daisy Jonkers ◽  
Paul Savelkoul ◽  
Marie J. Pierik ◽  
Ad Masclee ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Microbial Composition ◽  
Inflammatory Bowel ◽  
Over Time

scholarly journals Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence

2020 ◽  
Vol 11 (9) ◽  
pp. e00227
Author(s):  
Mafalda Santiago ◽  
Fernando Magro ◽  
Luís Correia ◽  
Francisco Portela ◽  
Paula Ministro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Reoperation Rate ◽  
Inflammatory Bowel ◽  
Over Time

Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time

2016 ◽  
Vol 52 (3) ◽  
pp. 344-350 ◽  
Author(s):  
Karin Amcoff ◽  
Mats Stridsberg ◽  
Maria Lampinen ◽  
Anders Magnuson ◽  
Marie Carlson ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Clinical Implications ◽  
Inflammatory Bowel ◽  
Over Time

scholarly journals An Esophagogastroduodenal Crohn’s-Like Disease in a Long-Standing Pan-Ulcerative Colitis Patient

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Christopher Moore ◽  
Shriram Jakate ◽  
Ali Keshavarzian
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Ulcerative Colitis Patient ◽  
Colitis Patient ◽  
Inflammatory Bowel ◽  
Over Time

Inflammatory bowel disease (IBD) comprises the principal subtypes Crohn’s disease (CD) and ulcerative colitis (UC), with a fraction remaining as IBD unclassified (IBDU). Given the complexity of IBD manifestations in a patient over time and our increasing understanding of IBD biology, a modification in subtype diagnosis can also occur. Herein is a case of a 27-year-old female with well-controlled and long-standing pan-UC, who developed Crohn’s-like esophagogastroduodenitis. The difficulty in classifying IBD into a single traditional subtype, and the debated presentation of a coexistent IBD will be discussed.

Sign in / Sign up

Export Citation Format

Share Document